Comparing two different BRCA1 mutations on N-terminal domain (185delAG and 5382insC) in genetically engineered mouse models, BRCA1 (185delAG) tumours responded significantly worse to PARPi than the BRCA1 (5382insC) tumours. The gene discussed is BRCA1; the disease is neoplasm.